Your browser doesn't support javascript.
loading
Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL).
Grobost, Vincent; Hammi, Sami; Pereira, Bruno; Guilhem, Alexandre; Duffau, Pierre; Seguier, Julie; Parrot, Antoine; Gautier, Giovanni; Alric, Laurent; Kerjouan, Mallorie; Le Guillou, Xavier; Simon, Delphine; Chaussavoine, Laurent; Rondeau-Lutz, Murielle; Leguy-Seguin, Vanessa; Delagrange, Laura; Lavigne, Christian; Maillard, Hélène; Dupuis-Girod, Sophie.
Afiliação
  • Grobost V; Service de Médecine Interne, Clermont-Ferrand University Hospital, CHU Estaing, 63000 Clermont-Ferrand, France. Electronic address: vgrobost@chu-clermontferrand.fr.
  • Hammi S; Department of Internal Medicine, Angers University Hospital, 49100 Angers, France.
  • Pereira B; Biostatistics Unit, Clermont-Ferrand University Hospital, 63000 Clermont-Ferrand, France.
  • Guilhem A; Hospices Civils de Lyon, Hôpital Femme-Mère-Enfants, Service de Génétique et centre de référence de la maladie de Rendu-Osler, 69677 Bron, France.
  • Duffau P; Bordeaux University Hospital, Internal Medicine and Clinical Immunology Department, Université de Bordeaux, CNRS ImmunoConcEpT UMR 5164, 33000 Bordeaux, France.
  • Seguier J; Département de Médecine Interne, Marseille University Hospital, 13000 Marseille, France.
  • Parrot A; Assistance Publique-Hôpitaux de Paris, Service de Pneumologie et Centre de Compétence de la Maladie de Rendu Osler, Hôpital Tenon, 75020 Paris, France.
  • Gautier G; Nantes Université, Nantes University Hospital, Department of Internal and Vascular Medicine, 44000 Nantes, France.
  • Alric L; Internal Medicine-Digestive Medicine, CHU Rangueil Toulouse 3 University, 31000 Toulouse, France.
  • Kerjouan M; Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 35000 Rennes, France.
  • Le Guillou X; Medical Genetics Department, University Hospital of Poitiers, 86000 Poitiers, France.
  • Simon D; Service de Médecine Interne, CHU Charles Nicolle, 76000 Rouen, France.
  • Chaussavoine L; Centre Hospitalier Universitaire de Caen Normandie, Service de Médecine Vasculaire, 14000 Caen, France.
  • Rondeau-Lutz M; Service de Médecine Interne, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, 67 091 Strasbourg cedex, France.
  • Leguy-Seguin V; Department of Internal Medicine, CHU François Mitterrand, 21000 Dijon, France.
  • Delagrange L; Hospices Civils de Lyon, Hôpital Femme-Mère-Enfants, Service de Génétique et centre de référence de la maladie de Rendu-Osler, 69677 Bron, France.
  • Lavigne C; Department of Internal Medicine, Angers University Hospital, 49100 Angers, France.
  • Maillard H; Department of Internal Medicine and Clinical Immunology, Referral Centre for rare systemic autoimmune diseases for North and North-West France (CeRAINO), CHU Lille, 59000, Lille, France.
  • Dupuis-Girod S; Hospices Civils de Lyon, Hôpital Femme-Mère-Enfants, Service de Génétique et centre de référence de la maladie de Rendu-Osler, 69677 Bron, France.
Thromb Res ; 229: 107-113, 2023 09.
Article em En | MEDLINE | ID: mdl-37437516
BACKGROUND: It is unclear whether hereditary hemorrhagic telangiectasia (HHT) patients can tolerate antithrombotic therapies (AT) including antiplatelet (AP) and/or anticoagulant (AC) agents. OBJECTIVES: Primary endpoint was tolerance to AT in HHT. Secondary endpoints were to identify factors associated with major bleeding events (MBE) and premature discontinuation of AT. METHODS: Retrospective multicenter study in French national HHT Registry patients exposed to AT. RESULTS: We included 126 patients with 180 courses of AT. Median follow-up was 24 [11-52] months. Mean age was 65.6 ± 13.1 years. The first 3 months of AT exposure had an increased risk of hospitalization for hemorrhage (p < 0.001) and transfusions (p < 0.001). MBE (n = 63) occurred more frequently in the first 3 months of AT exposure (p < 0.001). Premature discontinuation of AT occurred in 61 cases. Rate of premature discontinuation was 29 % under both AP and AT therapy but significantly higher under dual AP therapy (n = 4/7, 57 % p = 0.008). Risk factors for MBE were: age ≥ 60 years (HR 2.34 [1.12;4.87], p = 0.023), prior hospitalization in the 3 months before starting AT for hemorrhage (HR 3.59 [1.93;6.66], p < 0.001) or transfusion (HR 3.15 [1.61;6.18], p = 0.001), previous history of gastro-intestinal bleeding (HR 2.71 [1.57;4.65], p < 0.001) or MBE (HR 4.62 [2.68;7.98], p < 0.001). Frequency of MBE did not differ between groups except for a higher risk in the dual AP group (HR 3.92 [1.37;11.22], p = 0.011). CONCLUSION: Tolerance of AC or AP therapy was similar in HHT population but not dual AP therapy. We identified risk factors for MBE occurrence or premature discontinuation under AT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Telangiectasia Hemorrágica Hereditária Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Telangiectasia Hemorrágica Hereditária Idioma: En Ano de publicação: 2023 Tipo de documento: Article